clinical trial · NCT07128121
A Phase 2 Study to Describe the Safety and Immunogenicity of Respiratory Syncytial Virus Vaccine IN006 in Healthy Participants Aged 60 Years and Older
Shenzhen Shenxin Biotechnology Co., Ltd·phase2·active not recruiting·n = 500
Respiratory Syncytial Virus (RSV) InfectionRespiratory Syncytial Virus IN006 Bivalent mRNA Vaccine (IN006)Placebo
brief summary
The study will evaluate the safety, tolerability, and immunogenicity of 2 dose levels of IN006 in healthy participants who aged at 60 years or older; of a revaccination of IN006 given 12 months or 24 months after the initial vaccination.
started
Aug 13, 2025
primary completion
Oct 1, 2029
completion
Oct 1, 2029
last updated
Sep 9, 2025
official title
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Immunogenicity of the Respiratory Syncytial Virus IN006 Bivalent mRNA Vaccine (IN006) in Healthy Participants Aged 60 Years and Older
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol